Asymmetric imidazole-4,5-dicarboxamide derivatives as SARS-CoV-2 main protease inhibitors: design, synthesis and biological evaluation
P. Huynh, Phatcharin Khamplong, Minh-Hoang Phan, Thanh-Phuc Nguyen, Phuong Ngoc Lan Vu, Quang-Vinh Tang, Phumin Chamsodsai, Supaphorn Seetaha, Truong Lam Tuong, Thien Y. Vu, Duc-Duy Vo, Kiattawee Choowongkomon, Cam-Van Thi Vo · RSC Medicinal Chemistry · 2024
of 0.04 ± 0.013 μM. Enzyme kinetic and molecular docking studies were carried out to clarify the inhibitory mechanism and to prove that the compound interacts at the active site. We also performed cytotoxicity assay to confirm that these compounds are not toxic to human cells.